Drugs and the Liver: High Risk Patients and Transplantation

1. Risk assessment in liver transplantation focus on lung function; M. Langer. 2. Biochemical basis of hepatic ischemic/reperfusion injury; J.L. Gollan. 3. Donor rating and assessment of pretransplant prognosis by use of the MEGX test; M. Oellerich. 4. Significance of cyclosporine pharmacokinetics in liver transplantation; J. Grevel. 5. Cyclosporin toxicity and liver transplantation in high risk patients; D. Galmarini. 6. Drug treatment in liver transplanted patients; antihypertensitive therapy; G. Leonetti. 7. Bacteremia after liver transplantation; a few issues in selection of antibiotics for treatment and prophylaxis; S. Kusne. 8. Antiviral drugs; F. Dianzani. 9. The use of antiviral drugs in liver transplant patients; T. Wreghitt. 10. Drugs, fetal liver and reproduction; P.V. Grella. 11. Reproduction after transplantation; V. Scantlebury. 12. Reproduction after liver transplantation for B-virus hepatitis; G. Rossi. 13. 24-hour hypothermic preservation of rat liver with euro-collins and UW solutions. Comparative evaluation by 31P NMR spectroscopy, biochemical assays and light microscopy; P.J. Cozzone. 14. ATP content during the ischemic period as an indicator of liver viability. A phosphorus-31 NMR study; J.-L. Gallis. 15. Drugs and liver disease; S. Sherlock. 16. Liver disease and anticancer drug treatment; G. Powis. 17. Pharmacokinetics of anticancer agents in patients with impaired liver function; M. D'Incalci. 18. Pathogenesis and treatment of alcoholic liver disease; C.S. Lieber. 19. Liver fibrogenesis in chronic viral and alcoholic liver disease; G. Annoni. 20. Hepatocellular carcinoma; M. Colombo. 21. Treatment of iron dependent chronic liver disease; G. Fiorelli. 22. Liver transplantation for chronic liver disease; D.H. Van Thiel. 23. Practical uses of OKT3; C.O. Esquivel. 24. Histopathology of acute liver rejection (ALR) in OKT3 treated patients; B. Gridelli. 25. Spin-spin relaxation times as viability parameter of liver transplantation grafts. Investigation on a pig model; P. Holzmüller. 26. Urinary 6-B hydroxycortisol as a predictor of cyclosporine blood levels; D. Samuel. 27. Elucidation of the metabolic pathways of cyclosporin in vitro by human liver microsomes; U. Christians. 28. Fine-needle aspiration biopsy and hepatotoxicity of cyclosporin A in orthotopic liver transplantation; P. Palazzi. 29. Effect of FK 506 and cyclosporins on model membranes studied by nuclear magnetic resonance spectroscopy; L. Rossaro. Index.